The European Commission has approved Sanofi's Cenrifki (tolebrutinib) as the first medicine targeting disability progression in secondary progressive multiple sclerosis (SPMS) without relapses. Approval is based on positive phase 3 clinical trial results showing Cenrifki delays disability progression in non-relapsing SPMS patients. The drug will be available in Germany this year, with strict liver monitoring due to potential liver risks. This marks a significant advancement for SPMS patients who previously had limited treatment options for disability progression.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
The FDA has approved Sarclisa Escena, a subcutaneous formulation of the multiple myeloma drug Sarclisa, administered via the innovative CirCLIQ on-body injector (OBI). This is the first anticancer treatment approved for delivery through an on-body in...
